Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults
Abstract Introduction Atogepant is a calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine in adults in the USA, EU, and several other countries. The objectives of this study were to evaluate the pharmacokinetics (PK) and dose proportionality of atogep...
Saved in:
Main Authors: | Ramesh R. Boinpally, Brian McNamee |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2025-01-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40120-024-00699-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New specific migraine prevention: monoclonal antibodies against calcitonin gene-related peptide and its receptor
by: K. Ryliškienė, et al.
Published: (2019-12-01) -
Differentially localizing isoforms of the migraine component calcitonin gene-related peptide (CGRP), in the mouse trigeminal ganglion: βCGRP is translated but, unlike αCGRP, not sorted into axons
by: Sofia Lyng Wæver, et al.
Published: (2025-01-01) -
Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
by: Austėja Dapkutė, et al.
Published: (2021-12-01) -
Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study
by: David Kudrow, et al.
Published: (2024-11-01) -
Vertebral artery dissection in a patient with migraine treated with calcitonin gene-related peptide monoclonal antibody: a case report and FAERS database analysis
by: Daiki Tokuyasu, et al.
Published: (2025-01-01)